Skip to main content

Resistell closes successful financing round

| News

Resistell closes successful financing round

11.12.2018

Resistell has closed on oversubscribed seed financing round. The Basel-based startup is developing an antibiotic susceptibility test that is much faster than conventional tests.

Around 700,000 people die every year due to drug resistant infections. Resistell AG, a spin-off of the École polytechnique fédérale de Lausanne (EPFL), is developing a diagnostic device that can quickly and reliably test patients for antibiotic susceptibility and thus reduce the spreading of antibiotic resistance, according to a press release from the Occident Group. The investment company from Zug participated in Resistell’s seed financing round, together with Hemex AG and six private investors.

Resistell’s diagnostic device uses nanotechnology and Atomic Force Microscopy-based techniques to capture the movements of living bacteria. If an effective antibiotic is applied, the bacteria dies and their movements cease. Unlike conventional tests that take days to complete, the Resistell method delivers accurate results in just hours, allowing patients to be treated with the right medication from day one.

Founded in Basel in April 2018, Resistell was awarded a European patent for the device and method in summer 2018, making Resistell “perfectly placed to raise the funds needed for the next development stage”. Resistell will now move to new premises in Muttenz in the canton of Basel-Landschaft.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.